'Em­pa­thy and love were not shown’: The sto­ry be­hind Taysha’s lay­offs, one of dozens of biotechs suf­fer­ing this ...

4 years ago
Cell/Gene Tx
In Focus

Ab­b­Vie, Gen­mab tout ear­ly da­ta for bis­pe­cif­ic in a bid to leapfrog Re­gen­eron, Roche

4 years ago
R&D

Six months af­ter lift­ing hold, FDA wants to re­voke Pro­tag­o­nist's break­through ther­a­py des­ig­na­tion, biotech says

4 years ago
FDA+

Let’s build some­thing to­geth­er: Ex-Lowe’s CFO to join Pfiz­er while Mod­er­na’s David Meline re­tires; The ...

4 years ago
Peer Review

ARCH leads $130M in­fu­sion in­to Be Bio's long pur­suit of B cell ther­a­pies for rare dis­ease, can­cer

4 years ago
Financing
Startups

ICER finds blue­bird's po­ten­tial $2.1M gene ther­a­py cost-ef­fec­tive as FDA ad­comm sched­uled for June

4 years ago
Pharma
FDA+

Bi­par­ti­san group of law­mak­ers call on 7 man­u­fac­tur­ers to make opi­oid over­dose an­ti­dote OTC

4 years ago
Pharma

FDA ad­dress­es bio­phar­ma's di­ver­si­ty prob­lem with new draft guid­ance

4 years ago
Pharma
FDA+

Bay­er, GSK, No­var­tis and Roche jump­start bio­mark­er can­cer or­ga­ni­za­tion to dri­ve tests for all

4 years ago
Pharma
Marketing

How McK­in­sey used its FDA con­nec­tions to help opi­oid man­u­fac­tur­ers: New con­gres­sion­al re­port

4 years ago
FDA+

The nev­er-end­ing Zostavax sto­ry – in court. Mer­ck gets a win, but thou­sands more law­suits pend­ing

4 years ago
Pharma
Marketing

Take­da makes good on buy­back promise, snap­ping up near­ly $200M of its own shares

4 years ago
Pharma

CMS of­fi­cial on Alzheimer's drug cov­er­age de­ci­sion: Don't read be­tween the lines for oth­er ac­cel­er­at­ed ap­provals

4 years ago
Pharma

Turn­ing Point looks to chal­lenge Pfiz­er, Roche with new ear­ly da­ta for lead lung can­cer drug

4 years ago
R&D

Ab­b­Vie pres­i­dent Michael Sev­eri­no heads to Flag­ship as biotech in­cu­ba­tor's third CEO-part­ner in six days

4 years ago
People
Startups

AACR22: Af­ter Fer­Gene blowup, a start­up touts even bet­ter blad­der can­cer gene ther­a­py re­sults in tiny study

4 years ago
Startups
R&D

Af­ter Feb­ru­ary mar­ket crash, Pro­QR will lay off 30% of its work­force and try push­ing eye ther­a­py af­ter failed tri­al

4 years ago
People
R&D

Tiny Ok­la­homa com­pa­ny gets the eye of Boehringer In­gel­heim, sign­ing deal for re­gen­er­a­tive hear­ing loss treat­ment

4 years ago
Startups
Deals

'Tru­ly dif­fer­en­t': Roche's for­mer hema­tol­ogy leader shifts a new Ver­sant biotech in­to gear

4 years ago
Financing
Startups

In bid to re­make it­self af­ter pan­cre­at­ic can­cer flop, Halozyme ac­quires Antares and its drug de­liv­ery tech for $960M

4 years ago
Deals

As an­titrust case wraps, Mar­tin Shkre­li's lawyers say they're owed $2M+ in un­paid le­gal fees

4 years ago
People
Law

From $3M to $1.9B: Glax­o­SmithK­line in­serts dis­card­ed Gilead drug in­to late-stage port­fo­lio, buy­ing out the turn­around ...

4 years ago
Deals

RA, Jeito and Omega back a small Swiss biotech to en­ter an I/O field paved by Adap­ti­m­mune

4 years ago
Financing
Startups

FDA sends warn­ing to rogue phar­ma­cies sell­ing Adder­all il­le­gal­ly over the in­ter­net

4 years ago
FDA+
First page Previous page 549550551552553554555 Next page Last page
A service from the Financial Times